[
  {
    "column": "S7",
    "description": "S7: [pipe:S7Pipe]",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S8r1",
    "description": "S8r1: Federally Qualified Health Center (FQHC) / Community Health Center (CHC) - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r2",
    "description": "S8r2: Solo outpatient private practice - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r3",
    "description": "S8r3: Single-specialty group outpatient private practice - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r4",
    "description": "S8r4: Multi-specialty group outpatient private practice - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r5",
    "description": "S8r5: Inpatient hospital or psychiatric institution - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r6",
    "description": "S8r6: Nursing home / long-term care facility - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r7",
    "description": "S8r7: Emergency room or acute care center - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r8",
    "description": "S8r8: Other setting - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S9",
    "description": "S9: In a typical month, approximately how many adults (i.e., age 18 or older) do you actively manage care for who have been diagnosed according to the DSM-V criteria with Major Depressive Disorder (MDD)? Please do not include dysthymia or situational depr",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S10",
    "description": "S10: Of the adult patients with MDD you see in a typical month, approximately how many have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive episode?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S13r1c1",
    "description": "S13r1c1: Patients you personally treated with this - Spravato - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive epi",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r1c2",
    "description": "S13r1c2: Patients you refer to another provider in your practice to treat - Spravato - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r1c3",
    "description": "S13r1c3: Patients you refer to another provider outside your practice to treat - Spravato - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration withi",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r2c1",
    "description": "S13r2c1: Patients you personally treated with this - IV ketamine - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r2c2",
    "description": "S13r2c2: Patients you refer to another provider in your practice to treat - IV ketamine - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r2c3",
    "description": "S13r2c3: Patients you refer to another provider outside your practice to treat - IV ketamine - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration wi",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r3c1",
    "description": "S13r3c1: Patients you personally treated with this - Transcranial Magnetic Stimulation (TMS) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration wi",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r3c2",
    "description": "S13r3c2: Patients you refer to another provider in your practice to treat - Transcranial Magnetic Stimulation (TMS) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequa",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r3c3",
    "description": "S13r3c3: Patients you refer to another provider outside your practice to treat - Transcranial Magnetic Stimulation (TMS) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of a",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r4c1",
    "description": "S13r4c1: Patients you personally treated with this - Electroconvulsive therapy (ECT) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r4c2",
    "description": "S13r4c2: Patients you refer to another provider in your practice to treat - Electroconvulsive therapy (ECT) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "S13r4c3",
    "description": "S13r4c3: Patients you refer to another provider outside your practice to treat - Electroconvulsive therapy (ECT) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S13",
    "context": ""
  },
  {
    "column": "h13Sum1",
    "description": "h13Sum1: Product Referral Sum: Spravato",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "h13Sum2",
    "description": "h13Sum2: Product Referral Sum: IV ketamine",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "h13Sum3",
    "description": "h13Sum3: Product Referral Sum: Transcranial Magnetic Stimulation (TMS)",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "h13Sum4",
    "description": "h13Sum4: Product Referral Sum: Electroconvulsive therapy (ECT)",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "B12r1",
    "description": "B12r1: For the remainder of this survey, we are going to focus on treatment-resistant depression, which we’ll abbreviate as TRD. Using the slide below, how much do you agree with the definition below of treatment-resistant depression (TRD)? Treatment-Re",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B12",
    "context": ""
  },
  {
    "column": "A2",
    "description": "A2: Approximately what proportion of your TRD visits are conducted via tele-health (remotely, by Zoom, etc.) as opposed to in person?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "A4r1",
    "description": "A4r1: How many times per year, on average, do you see your typical TRD patients?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "hB3Count",
    "description": "hB3Count: B3: # of items selected",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "B6r1",
    "description": "B6r1: Selective serotonin reuptake inhibitors (SSRIs) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r2",
    "description": "B6r2: Serotonin and norepinephrine reuptake inhibitors (SNRIs) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both tr",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r3",
    "description": "B6r3: Dopaminergic/noradrenergic agents - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r4",
    "description": "B6r4: Trintellix (vortioxetine) and/or Viibryd (vilazodone) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treat",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r5",
    "description": "B6r5: Wellbutrin (bupropion) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patient",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r6",
    "description": "B6r6: Atypical antipsychotics (e.g., Vraylar, Rexulti) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r7",
    "description": "B6r7: Auvelity (dextromethorphan – bupropion) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and re",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r8",
    "description": "B6r8: Spravato (esketamine) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patients",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r9",
    "description": "B6r9: IV Ketamine - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patients under you",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r10",
    "description": "B6r10: Transcranial Magnetic Stimulation (TMS) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and ref",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r11",
    "description": "B6r11: Electroconvulsive Therapy (ECT) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals f",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6r13",
    "description": "B6r13: Other - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patients under your car",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6",
    "context": ""
  },
  {
    "column": "B6ar1",
    "description": "B6ar1: Abilify (aripiprazole) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6a",
    "context": ""
  },
  {
    "column": "B6ar2",
    "description": "B6ar2: Seroquel (Quetiapine XR/ER) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6a",
    "context": ""
  },
  {
    "column": "B6ar3",
    "description": "B6ar3: Rexulti (Brexpiprazole) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6a",
    "context": ""
  },
  {
    "column": "B6ar4",
    "description": "B6ar4: Vraylar (cariprazine) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6a",
    "context": ""
  },
  {
    "column": "B6ar8",
    "description": "B6ar8: Risperdal (Risperidone) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6a",
    "context": ""
  },
  {
    "column": "B6ar7",
    "description": "B6ar7: Other - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B6a",
    "context": ""
  },
  {
    "column": "B7r1",
    "description": "B7r1: % who you diagnosed personally or via internal practice referral - Of your Spravato patients, what percent fall into each group below?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7",
    "context": ""
  },
  {
    "column": "B7r2",
    "description": "B7r2: % who were referred to your care from outside your practice - Of your Spravato patients, what percent fall into each group below?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7",
    "context": ""
  },
  {
    "column": "C5r1c1",
    "description": "C5r1c1: Selective serotonin reuptake inhibitors (SSRIs) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Ple",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r2c1",
    "description": "C5r2c1: Serotonin and norepinephrine reuptake inhibitors (SNRIs) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 mo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r3c1",
    "description": "C5r3c1: Dopaminergic/$ {\"\" if gv.request.device.isMobileDevice() else \"\"}noradrenergic agents - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r4c1",
    "description": "C5r4c1: Trintellix (vortioxetine) and/or Viibryd (vilazodone) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 month",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r5c1",
    "description": "C5r5c1: Wellbutrin (bupropion) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatme",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r6c1",
    "description": "C5r6c1: Atypical antipsychotics - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatm",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r7c1",
    "description": "C5r7c1: Auvelity (dextromethorphan – bupropion) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please co",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r8c1",
    "description": "C5r8c1: Spravato (esketamine) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatmen",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r9c1",
    "description": "C5r9c1: IV Ketamine - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments and ref",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r10c1",
    "description": "C5r10c1: Transcranial Magnetic Stimulation (TMS) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please con",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r11c1",
    "description": "C5r11c1: Electroconvulsive Therapy (ECT) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider bo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r12c1",
    "description": "C5r12c1: Other - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments and referral",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r1c2",
    "description": "C5r1c2: Selective serotonin reuptake inhibitors (SSRIs) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 mont",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r2c2",
    "description": "C5r2c2: Serotonin and norepinephrine reuptake inhibitors (SNRIs) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the nex",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r3c2",
    "description": "C5r3c2: Dopaminergic/$ {\"\" if gv.request.device.isMobileDevice() else \"\"}noradrenergic agents - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r4c2",
    "description": "C5r4c2: Trintellix (vortioxetine) and/or Viibryd (vilazodone) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 1",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r5c2",
    "description": "C5r5c2: Wellbutrin (bupropion) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r6c2",
    "description": "C5r6c2: Atypical antipsychotics - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r7c2",
    "description": "C5r7c2: Auvelity (dextromethorphan – bupropion) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Pl",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r8c2",
    "description": "C5r8c2: Spravato (esketamine) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both t",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r9c2",
    "description": "C5r9c2: IV Ketamine - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r10c2",
    "description": "C5r10c2: Transcranial Magnetic Stimulation (TMS) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Ple",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r11c2",
    "description": "C5r11c2: Electroconvulsive Therapy (ECT) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please cons",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C5r12c2",
    "description": "C5r12c2: Other - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments and r",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "hC5_8Spravato",
    "description": "hC5_8Spravato: C5_8: Change in Spravato – C5_8 minus B6_8",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "hC10Count",
    "description": "hC10Count: C10: # of items selected",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "hC11Count",
    "description": "hC11Count: C11: # of items selected",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "C12",
    "description": "C12: Please think about the MDD patients who have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive episode for whom you have referred for Spravato. To the best of your knowledge",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "D2r1",
    "description": "D2r1: Aware of patient support programs for patients with treatment-resistant MDD - What percentage of your TRD patients would you say are…",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D2",
    "context": ""
  },
  {
    "column": "D2r2",
    "description": "D2r2: Enrolled in one or more patient support programs for patients with treatment-resistant MDD - What percentage of your TRD patients would you say are…",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D2",
    "context": ""
  },
  {
    "column": "D2r3",
    "description": "D2r3: Neither aware nor enrolled in patient support programs for patients with treatment-resistant MDD - What percentage of your TRD patients would you say are…",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D2",
    "context": ""
  },
  {
    "column": "E1",
    "description": "E1: On average, how many hours per month in total do you spend on keeping abreast of medical developments or medical education, specifically related to MDD / TRD? This would include any of the following activities: Reading medical journals Reviewing new c",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "E3",
    "description": "E3: In a typical year, how many medical conferences, congresses or seminars do you attend where MDD / TRD is a topic of discussion?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "E5",
    "description": "E5: In a typical 3-month period, approximately how many representatives do you personally see from pharmaceutical companies? Please think only about those representatives with whom you have some type of interaction, whether it is signing for samples, disc",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "E6",
    "description": "E6: In the past 3 months, approximately how many times have you been visited by a pharmaceutical representative specifically from Spravato?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "hE7Count",
    "description": "hE7Count: E7: # of items selected",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "F1",
    "description": "F1: [pipe:S7Pipe]",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "F7r1",
    "description": "F7r1: Physicians - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F7",
    "context": ""
  },
  {
    "column": "F7r5",
    "description": "F7r5: Therapists - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F7",
    "context": ""
  },
  {
    "column": "F7r2",
    "description": "F7r2: Nurses or Medical Assistants - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F7",
    "context": ""
  },
  {
    "column": "F7r3",
    "description": "F7r3: Nurse Practitioners/Physicians Assistants - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F7",
    "context": ""
  },
  {
    "column": "F7r4",
    "description": "F7r4: Administrative Staff - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F7",
    "context": ""
  },
  {
    "column": "hF7Sum",
    "description": "hF7Sum: F7: Sum of staff",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "F12r1",
    "description": "F12r1: No coverage / cash paying - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r2",
    "description": "F12r2: Commercial insurance (HMO, PPO, or other private insurance – may be a Medicare supplement) - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r3",
    "description": "F12r3: Medicaid / Public Aid - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r4",
    "description": "F12r4: Traditional Medicare - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r5",
    "description": "F12r5: Medicare Advantage - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r6",
    "description": "F12r6: VA (Veterans’ Administration) or Department of Defense - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r7",
    "description": "F12r7: Other - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "hF12Sum",
    "description": "hF12Sum: F12: Medicare NET – sum of 4+5",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  }
]